Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.50 EUR
Change Today +0.143 / 6.07%
Volume 254.6K
PA8 On Other Exchanges
Symbol
Exchange
Xetra
OTC US
As of 2:05 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

paion ag (PA8) Snapshot

Open
€2.36
Previous Close
€2.36
Day High
€2.51
Day Low
€2.35
52 Week High
09/23/14 - €3.43
52 Week Low
10/10/14 - €1.66
Market Cap
126.6M
Average Volume 10 Days
185.3K
EPS TTM
€-0.24
Shares Outstanding
50.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PAION AG (PA8)

Related News

No related news articles were found.

paion ag (PA8) Related Businessweek News

No Related Businessweek News Found

paion ag (PA8) Details

Paion AG, a specialty pharma company, develops and commercializes drug candidates for diseases or interventions. Its product candidates include Remimazolam, an ultra short-acting general anaesthetic/sedative agent, which is under various clinical studies and developed to be used in general anesthesia (deep and long sedation of up to several hours) and procedural sedation (short sedation of up to about 30 minutes) in short procedures, such as colonoscopies applications; and Glial Growth Factor 2 that completed Phase I trials to stimulate the growth and differentiation of various cells, including glial cells. Paion AG was founded in 2000 and is headquartered in Aachen, Germany.

26 Employees
Last Reported Date: 05/13/15
Founded in 2000

paion ag (PA8) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €370.0K
Co-Founder, Chief Medical Officer and Member ...
Total Annual Compensation: €340.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €50.0K
Compensation as of Fiscal Year 2014.

paion ag (PA8) Key Developments

Mariola Söhngen to Leave Management Board of Paion AG as of 31 October 2015

PAION AG announced that Dr. Mariola Sohngen, Chief Medical Officer and co-founder of the company, has informed the Chairman of the Supervisory Board that she wants to leave the Management Board of the company prior to the end of her current appointment until 31 December 2016 to pursue a new management opportunity at another company that is not competing with PIAON. The Supervisory Board has basically agreed with Mrs. Sohngen that she will resign from office as of 31 October 2015. The details of the termination agreement will be agreed between the Supervisory Board and Mrs. Sohngen. Mrs. Sohngen will continue to provide her expertise as a consultant on request after her departure. In connection with the step-down of Mrs. Sohngen, the Supervisory Board decided to extend the appointment and contract of Mr. Sohngen as CEO of the company by another year until end of 2018. In the interim, Mr. Sohngen will take over certain of Mrs. Sohngen's functions until the appointment of a new CMO and thus will ensure a smooth transition.

Paion AG Presents at BIO International Convention 2015, Jun-16-2015 11:30 AM

Paion AG Presents at BIO International Convention 2015, Jun-16-2015 11:30 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Wolfgang Söhngen, Co-Founder, Chairman of Management Board and Chief Executive Officer.

Paion AG Announces Initiation of Second U.S. Phase III Clinical Trial of Remimazolam for Procedural Sedation During Bronchoscopy

PAION AG announced the initiation of the second pivotal U.S. Phase III clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing bronchoscopy. The current trial forms the second pivotal study of the Remimazolam Phase III program. PAION and the U.S. Food and Drug Administration (FDA) have agreed on the remaining development program (indications, size of studies and design). This Phase III clinical trial is a prospective, double-blind, randomized, placebo- and midazolam-controlled, U.S. multicenter study in 460 patients undergoing bronchoscopies. Patients will be randomized to receive Remimazolam, midazolam or placebo in addition to fentanyl to achieve moderate sedation. The primary endpoint is the successful completion of the bronchoscopy procedure with no requirement for an alternative sedative. The completion of patient recruitment is expected in 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PA8:GR €2.50 EUR +0.143

PA8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PA8.
View Industry Companies
 

Industry Analysis

PA8

Industry Average

Valuation PA8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.1x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAION AG, please visit www.paion.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.